Biological MArkers of FRAilty in Elderly Subjects

Overview

Epidemiological data from Europe have shown that around 30% of subjects aged over 65 years of age are pre-frail, and 15% are frail. Recent research has demonstrated that identifying frailty and implementing preventive measures can help to slow cognitive decline. Screening and treating frailty seem to be a good start towards preventing dependency.

On the premise that this frailty is the result of more pronounced tissue alterations in certain elderly subjects, assessment of post-translational modification derived products (PTMDP) represents an innovative evaluation method. These include advanced glycation end-products (AGE), and carbamylation-derived products (homocitrulline). Indeed, the intensity of these modifications increases with ageing, and assessing the products resulting from these alterations could show the existence of differences according to frailty status. This would make it possible to adapt treatment accordingly in elderly subjects.

Full Title of Study: “PTMDP (Post-translational Modification Derived Products) as Markers of Frailty in Elderly Subjects”

Study Type

  • Study Type: Interventional
  • Study Design
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Diagnostic
    • Masking: None (Open Label)
  • Study Primary Completion Date: May 2019

Interventions

  • Other: Blood collection

Arms, Groups and Cohorts

  • Experimental: elderly subjects

Clinical Trial Outcome Measures

Primary Measures

  • post-translational modification derived-products (PTMDP) quantification by Multidimensional Chromatography Coupled withTandem Mass Spectrometry (LC/LC-MS/MS)
    • Time Frame: baseline

Participating in This Clinical Trial

Inclusion Criteria

  • With social security coverage
  • Accept to participate in the study and sign informed consent for the study and for the collection of biological samples

Exclusion Criteria

  • < 65 yo

Gender Eligibility: All

Minimum Age: 65 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • CHU de Reims
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Contact(s)
    • Rachid MAHMOUDI, rmahmoudi@chu-reims.fr

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.